The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

Cerus Corporation is an American multinational biotechnology company headquartered in Concord, California that develops and provides a treatment system to pathogen-reduce human blood products …

4 days ago · Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the …

4 days ago · Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The firm produces blood system for platelets and plasma.

5 days ago · Looking ahead, Cerus expects full-year 2026 product revenue to range between $224 million and $228 million, representing anticipated growth of 9% to 11% over 2025. IFC revenue is …

3 days ago · Image from MarketBeat Media, LLC. Cerus Corporation (NASDAQ:CERS - Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday . The company traded …

4 days ago · Cerus (CERS) Q4/FY revenue preview: blood safety growth led by INTERCEPT Fibrinogen Complex; FY2026 guide $224–$228M.

5 days ago · CONCORD, Calif., January 11, 2026--Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2025, as well as provided …

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company.

1 day ago · Get latest Cerus Corporation (CERS) stock price, news, and charts. Access real-time quotes and historical data with interactive charts and tools to make informed trading decisions.